ADMA Biologics' SEC filings document its specialty biologics business through Form 8-K reports on operating and financial results, FDA-related disclosures for ASCENIV, Regulation FD materials and other material-event updates. These records include disclosures tied to product revenue trends, immune globulin market conditions, commercial distribution, plasma collection and biomanufacturing operations.
ADMA's definitive proxy materials cover annual meeting matters, board and governance proposals, voting procedures and executive compensation. Its current reports also document executive transitions, related agreements, capital-structure matters, share-repurchase activity and risk-oriented product disclosures associated with immune globulin products.
ADMA Biologics (ADMA) Form 4 filing: CFO & Treasurer Brad L. Tade reported an automatic disposition of 7,123 common shares on 07/24/2025 using transaction code “F”, which indicates shares were withheld by the issuer solely to satisfy payroll-tax obligations triggered by restricted-stock-unit (RSU) vesting. The shares were valued at $17.31, an implied $123 k transaction value.
Following the tax withholding, Tade directly owns 239,419 shares. This total includes about 204,027 unvested RSUs granted in 2023-2025 that vest quarterly over four-year periods, plus 35,392 previously acquired shares. No derivative securities were bought or sold, and no open-market activity occurred.
The filing is routine, involves no cash proceeds to the insider, does not alter the company’s share count, and has limited market impact.
Form 4 overview: ADMA Biologics (ticker ADMA) disclosed that Chief Financial Officer & Treasurer Brad L. Tade had 9,838 common shares withheld on 06/26/2025 (transaction code “F”). The “F” code means the shares were automatically surrendered to the company to satisfy statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs); it was not an open-market sale.
Post-transaction holdings: Tade’s stated beneficial ownership is 246,542 shares after the withholding event. This figure comprises:
- 186,127 unvested RSUs spread across four grant dates (June 2023, Feb 2024, July 2024, Feb 2025) that vest quarterly over four years, contingent on continued employment.
- 24,415 fully vested shares accumulated through open-market purchases and past RSU settlements.
- The remaining balance represents fully vested shares already held.
No derivative activity was reported in Table II, and there were no purchases or sales of stock options or other instruments.
Investor takeaway: The filing is routine and signals mandatory tax withholding rather than discretionary selling. Insider equity alignment remains intact; the CFO continues to hold a meaningful stake that will grow as RSUs vest.
ADMA Biologics (ADMA) President and CEO Adam S. Grossman reported multiple transactions on June 16, 2025, executed under a pre-established Rule 10b5-1 trading plan from December 2024. The transactions included:
- Exercise of stock options for 15,000 shares at $5.40 per share
- Sale of 21,000 total shares at $20.81 per share
- Post-transaction direct ownership of 2,043,850 shares
- Indirect ownership of 1,143,426 shares through Areth LLC and 580,957 shares through Hariden LLC
Grossman maintains significant equity positions including unvested RSUs totaling over 1 million shares granted between 2022-2025, vesting quarterly over four years. He also holds 810,950 stock options granted February 2024 at $5.40/share, vesting through February 2028. The transactions demonstrate a routine exercise-and-sell pattern while maintaining substantial long-term ownership.